Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA)

儿童艾滋病毒/艾滋病

• 批准号: 10223896
• 负责人: CARL E ALLEN
• 金额: $ 110.43万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-25 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10223896
• 关键词: AIDS related cancer; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adolescent; Affect; Africa South of the Sahara; African; Biometry; Botswana; Cancer Patient; Caring; Child; Childhood; Clinical Research; Collaborations; Complement; Country; Descriptive Epidemiology; Developmental Diagnostic; Diagnosis; Education; Epidemic; Fellowship; Fellowship Program; Goals; HIV; HIV Infections; HIV diagnosis; Healthcare; Hematological Disease; Hematology; Incidence; Infrastructure; International; Kaposi Sarcoma; Laboratories; Lead; Lymphoma; Malawi; Malignant Childhood Neoplasm; Malignant Neoplasms; Modeling; Oncology; Outcome; Patient-Focused Outcomes; Patients; Pediatric Hematology; Pediatric Hospitals; Pediatric Oncologist; Pediatric Oncology; Pediatric Oncology Group; Research; Research Project Grants; Research Training; Resources; Risk; Risk Factors; Site; Texas; Training; Training Programs; Translational Research; Uganda; Work; base; cancer care; cancer epidemiology; cancer survival; career development; clinical infrastructure; design; improved; improved outcome; infection related cancer; medical specialties; mortality; operation; overtreatment; patient population; pediatric human immunodeficiency virus; pediatric patients; programs; risk stratification; success; training opportunity

Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for Sub-Saharan Africa (PARCA) The goal of this proposal is to establish PARCA, a collaborative clinical and translational research framework designed with the overarching goal to improve the current unacceptably poor outcomes of children with HIV- associated malignancies in sub-Saharan Africa (SSA). Currently, over 80% of children with cancer in the US survive, whereas over 80% in the majority of SSA countries die. To begin to address this disparity and improve outcomes for children with cancer in SSA, Texas Children's Hospital leveraged the clinical infrastructure of BIPAI in Uganda, Malawi, and Botswana to establish Global HOPE (Hematology-Oncology Pediatric Excellence). Global HOPE is dedicated to excellence in the care and treatment of children globally with cancer and blood disorders through state-of-the-art treatments and cutting-edge research. These three Global HOPE pediatric cancer programs, which treat patients nationwide, have begun to transform cancer care in SSA. In the US, improvements in pediatric cancer survival were achieved largely through clinical and translational research coordinated by cooperative groups such as the Children's Oncology Group. Following that model, we propose to establish a framework for collaboration to enable advances for children in SSA living with HIV and diagnosed with cancer through PARCA. The Overarching Goals of the Consortium are to: 1. Define the descriptive epidemiology and infectious exposures related to pediatric malignancies in SSA. We will determine the incidence and outcomes of HIV-associated malignancy across the BIPAI network in SSA. 2. Conduct transformative inter-disciplinary collaborative research to reduce the burden of KS and lymphoma among children and adolescents in SSA. We will establish multi-center strategies for diagnosis, risk- stratification, and outcomes improvement for children with Kaposi sarcoma and lymphoma. These studies will be best conducted in Uganda, Malawi, and Botswana, where the pediatric patient population is large enough to establish meaningful results and conclusions. Validated results will be disseminated throughout our Global HOPE network, as it continues to expand operations in SSA. 3. Support the formation of a multi-national collaborative resource in clinical and translational research, training, and career development for African scientific leaders in HIV and pediatric cancer. We will provide myriad research and training opportunities for pediatric oncologists throughout SSA to participate in and lead translational and clinical research. This program of scientific training will complement and supplement the continued success of Global HOPE Paediatric Haematology and Oncology Fellowship Program.

撒哈拉以南非洲儿童艾滋病毒/艾滋病和感染相关恶性肿瘤研究联盟 (帕尔卡) 这项提议的目标是建立PARCA，一个协作的临床和翻译研究框架 设计的总体目标是改善目前艾滋病毒感染儿童令人无法接受的糟糕结果- 撒哈拉以南非洲的相关恶性肿瘤(SSA)。目前，美国80%以上的癌症儿童 在大多数南沙群岛国家中，80%以上的人死亡。开始解决这一差距并改善 在SSA，德克萨斯儿童医院利用临床基础设施 BIPAI在乌干达、马拉维和博茨瓦纳建立全球希望(血液学-肿瘤学儿科 卓越)。全球希望致力于在全球癌症儿童的护理和治疗方面取得卓越成就 和血液疾病，通过最先进的治疗和尖端研究。这三个全球希望 在全国范围内治疗患者的儿科癌症项目已经开始改变SSA的癌症护理。在 在美国，儿童癌症存活率的改善主要是通过临床和转译研究实现的 由儿童肿瘤学小组等合作小组协调。遵循这一模式，我们建议 建立一个合作框架，以促进SSA艾滋病毒携带者儿童的进展，并 通过PARCA被诊断为癌症。 该联盟的首要目标是： 1.界定SSA中与儿科恶性肿瘤相关的描述性流行病学和感染性暴露。我们 将确定SSA整个BIPAI网络中艾滋病毒相关恶性肿瘤的发生率和结果。 2.开展变革性跨学科协作研究，减轻KS和淋巴瘤负担 在SSA的儿童和青少年中。我们将建立多中心战略来诊断、风险和 对患有卡波西肉瘤和淋巴瘤的儿童进行分层治疗和改善预后。这些研究 最好是在乌干达、马拉维和博茨瓦纳进行，这些国家的儿科患者人数很多 足以确立有意义的结果和结论。经过验证的结果将在 我们的全球希望网络，因为它继续扩大在南沙的业务。 3.支持形成临床和转化性研究的多国协同资源， 在艾滋病毒和儿科癌症方面为非洲科学领袖提供培训和职业发展。我们将提供 为整个SSA的儿科肿瘤学家提供无数的研究和培训机会，以参与和 领导翻译和临床研究。这一科学训练方案将是一种补充和补充 全球希望儿科血液学和肿瘤学奖学金计划的持续成功。